Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study

Abstract Background Checkpoint inhibitors (CPIs) are widely used in cancer treatment, with transformative impacts on survival. They nonetheless carry a significant risk of toxicity in the form of immune-related adverse events (IrAEs), which may be sustained and life-altering. IrAEs may require high-...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Abigail Gault, Linda Hogarth, Kristian C Williams, Alastair Greystoke, Neil Rajan, Ally Speight, Christopher A Lamb, Alison Bridgewood, Lisa-Jayne Brown-Schofield, Fiona Rayner, John D Isaacs, Jérémie Nsengimana, Christopher J Stewart, Amy E Anderson, Ruth Plummer, Arthur G Pratt
Format:	Article
Language:	English
Published:	BMC 2024-06-01
Subjects:	Checkpoint inhibitor Immunotherapy Cancer Immune related adverse events Pathogenesis Cohort study
Online Access:	https://doi.org/10.1186/s12885-024-12468-3